Analysed ATEA PHARMACEUTICALS INC (AVIR:NASDAQ) News Sources
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
27-05-2026
yahoo.com
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
25-06-2026
yahoo.com
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
14-07-2026
yahoo.com
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
28-07-2026
yahoo.com
Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial
28-07-2026
yahoo.com
What is the current price of ATEA PHARMACEUTICALS INC (AVIR:NASDAQ)?
The current price of ATEA PHARMACEUTICALS INC (AVIR:NASDAQ) is $4.7.
ATEA PHARMACEUTICALS INC (AVIR:NASDAQ) absolute price change since previous trading day?
The absolute price change of ATEA PHARMACEUTICALS INC (AVIR:NASDAQ) since the previous trading day is $-0.04.
ATEA PHARMACEUTICALS INC (AVIR:NASDAQ) percentage price change since previous trading day?
The percentage price change of ATEA PHARMACEUTICALS INC (AVIR:NASDAQ) since the previous trading day is -0.8439%.
What is the most recent average sentiment score for ATEA PHARMACEUTICALS INC (AVIR:NASDAQ)?
The most recent average sentiment score for ATEA PHARMACEUTICALS INC (AVIR:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for ATEA PHARMACEUTICALS INC (AVIR:NASDAQ)?
The most recent sentiment for ATEA PHARMACEUTICALS INC (AVIR:NASDAQ) is .
SEC-8K** Filing Available For ATEA PHARMACEUTICALS INC (AVIR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.